SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Steve Fancy who wrote (4507)6/17/1998 12:08:00 PM
From: Bhag Karamchandani  Read Replies (2) | Respond to of 6136
 
"Agouron said disease was stabilized in more than 25% of 47 patients in a Phase I study on patients with advanced lung, prostate, kidney and colorectal cancers and sarcoma and melanoma.The patients were treated for periods of 16 to 40 weeks."
Can some one offer an empirical definition of " stabilized" ?Are there published research abstracts available??



To: Steve Fancy who wrote (4507)6/17/1998 12:29:00 PM
From: sam  Read Replies (2) | Respond to of 6136
 
Monthly script data looks great. NUMBERS ARE ROUNDED, as told to me via telephone call with PW. Viracept market share: 31.3%. Total scripts: about 48,000 (up 4.7%). New scripts: about 17,700 (up 5.3%). Refills: about 30,300 (up 4.4%).


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News